title: Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy.
abstract: BACKGROUND
  The clinical efficacy of alcohol septal ablation for drug-refractory hypertrophic cardiomyopathy remains unclear. This study examines the outcome of alcohol septal ablation performed at a tertiary hypertrophic cardiomyopathy referral center.
  
  
  RESULTS
  Among 601 patients with severely symptomatic obstructive hypertrophic cardiomyopathy referred for alcohol septal ablation or myectomy from 1998 to 2006, 138 patients (median age, 64 years; 39% men) chose to undergo ablation. Procedural complications included death in 1.4%, sustained ventricular arrhythmias in 3%, tamponade in 3%, and pacemaker implantation in 20%. This rate was higher than a combined complication rate of 5% in age- and gender-matched patients who had undergone septal myectomy at Mayo Clinic (P<0.0001). Four-year survival free of all mortality was 88.0% (95% confidence interval, 79.4 to 97.5%), which was similar to that of the age- and gender-matched patients who had undergone myectomy (P=0.18). Six patients had documented ventricular arrhythmias after ablation, 4 of whom had successful intervention. Four-year survival free of death and severe New York Heart Association class III/IV symptoms after septal ablation was 76.4%, and 71 patients (51%) became asymptomatic. Myectomy patients <or=65 years of age had significantly better survival free of death and severe symptoms (P=0.01).
  
  
  CONCLUSIONS
  Alcohol septal ablation is an efficacious procedure if performed in an experienced institution and may resolve symptoms in a subset of patients with obstructive hypertrophic cardiomyopathy. However, the procedural complication rate exceeds that of myectomy. Patients 65 years of age have better symptom resolution with myectomy. No impairment in short-term survival was noted in this nonrandomized study, but the long-term outcome remains unknown.
authors.affiliation: Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA. paul.sorajja@mayo.edu
authors.forename: Paul
authors.initials: P
authors.lastname: Sorajja
authors.forename: Uma
authors.initials: U
authors.lastname: Valeti
authors.forename: Rick A
authors.initials: RA
authors.lastname: Nishimura
authors.forename: Steve R
authors.initials: SR
authors.lastname: Ommen
authors.forename: Charanjit S
authors.initials: CS
authors.lastname: Rihal
authors.forename: Bernard J
authors.initials: BJ
authors.lastname: Gersh
authors.forename: David O
authors.initials: DO
authors.lastname: Hodge
authors.forename: Hartzell V
authors.initials: HV
authors.lastname: Schaff
authors.forename: David R
authors.initials: DR
authors.lastname: Holmes
mesh_terms: D000367:Age Factors; D000368:Aged; D000438:Alcohols; D001145:Arrhythmias, Cardiac / Q000209:etiology; D002312:Cardiomyopathy, Hypertrophic / Q000401:mortality / Q000628:therapy*; D017115:Catheter Ablation / Q000009:adverse effects / Q000379:methods* / Q000401:mortality; D005260:Female; D006346:Heart Septum; D006801:Humans; D008297:Male; D008875:Middle Aged; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000438:Alcohols